Progress of research on human parvovirus B19 infection after renal transplantation

Abstract

Long-term immunosuppressant use in renal transplant recipients leads to dampened immune function and high susceptibility to opportunistic pathogens. Recently, the incidence of human parvovirus B19 (HPV-B19) infection after renal transplantation has increased, which may lead to pure red cell aplasia (PRCA), affect graft function, and lead to renal injury. After renal transplantation, the clinical manifestations of HPV-B19 infection are atypical, challenging the diagnosis and treatment. Therefore, we aimed to provide a comprehensive review of the existing literature to aid in the diagnosis and treatment of HPV-B19 infection after renal transplantation. To this end, we have described various aspects of HPV-B19 infection after renal transplantation ranging from the etiology, epidemiology, clinical manifestations, diagnosis, and treatment, to its prevention post renal transplant.

Keywords: Foscarnet; Human parvovirus B19; Intravenous immunoglobulin (IVIG); Mycophenolate mofetil (MMF); Pure red cell aplasia (PRCA); Renal transplantation; Tacrolimus.